
Anne Herold Li
Shareholder & NY Managing Partner, Brownstein Hyatt Farber Schreck | Co-Chair, Life Sciences Practice
Anne Herold Li is a shareholder at Brownstein Hyatt Farber Schreck, where she serves as managing partner of the firm’s New York office and co-chairs its Life Sciences practice. A first-chair trial lawyer and member of a Chambers-ranked patent team, she focuses on intellectual property and litigation in the life-sciences industry. She trained and worked as an epidemiologist before becoming a lawyer, and holds her law degree from Fordham University School of Law.
Her practice spans patent litigation, intellectual-property strategy, and the structuring of complex life-sciences transactions, work that places her at the center of the trade, tariff, and national-security questions now reshaping the industry. At the time of her appearance she was working on the Supreme Court cases over the administration’s tariffs, on behalf of a range of clients.
Herold Li appeared on Open Door Salon alongside Colin Zick, a partner at Foley Hoag, for a wide-ranging conversation on the legal and regulatory forces reshaping life sciences. She walked through what a tariff reversal would mean for the more than 300,000 companies that had paid them, the revival of the Bayh-Dole Act as a lever to force domestic manufacturing of federally funded inventions, and how dealmakers can structure China-linked biotech transactions around the returning Biosecure Act.
Her throughline was practical: the legal landscape is shifting on many fronts at once, but each shift creates a structuring or positioning question that a well-advised company can get ahead of rather than be caught by.
On Open Door Salon
“Everything Everywhere All at Once”
Colin Zick & Anne Herold Li · February 3, 2026
Episode page & show notes on Open Door Salon
In this episode
- The Supreme Court tariff cases and the IEEPA question
- 300,000+ companies filing to get tariff payments back
- Reviving the Bayh-Dole Act to force domestic manufacturing
- A floated "patent tax" on federally funded inventions
- Onshoring in many flavors, not just tariffs
- Structuring China-linked biotech deals around Biosecure
- The five-year Biosecure implementation window
- Getting ahead of the next disruption
Topics
Watch on Open Door Salon
Open Door Salon brings life-sciences leaders into candid conversation. Every Monday, the week's takeaways land in your inbox.
Subscribe on Substack →